Response to febuxostat according to clinical subtypes of hyperuricemia: a prospective cohort study in primary gout
Han Qi(Qingdao University), Changgui Li(Qingdao University), Zhaotong Jia(Qingdao University), Ruixia Sun(Qingdao University), Xiaomei Xue(Qingdao University), Lingling Cui(Tongji Hospital), Robert Terkeltaub(VA San Diego Healthcare System), Nicola Dalbeth(University of Auckland), Mingshu Sun(Qingdao University), Ying Chen(Qingdao University), Xiaoyu Cheng(Second Affiliated Hospital of Zhejiang University), Fei Yan(Qingdao University), Lidan Ma(Qingdao University), Yuwei He(Qingdao University), Tian Liu(Qingdao University), Xinde Li(Qingdao University)
Cited by 10
Related Papers
GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes
|Annals of the Rheumatic Diseases|2016|173
Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease
|The American Journal of Medicine|2021|122
Parathyroid hormone–related peptide is a naturally occurring, protein kinase A–dependent angiogenesis inhibitor
|Nature Medicine|2002|102